An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- …
Akari Therapeutics Announces $5.5 Million Private Placement Offering
TAMPA, FL and LONDON – May 21, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with …
[Read more...] about Akari Therapeutics Announces $5.5 Million Private Placement Offering
Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase
Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here TAMPA, …
[Read more...] about Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications TAMPA, FL …
Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload
Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancerApproval strengthens …
